Qing Bile Therapeutics

Qing Bile Therapeutics is a clinical-stage biotechnology company focused on developing novel therapeutics for cholestatic and metabolic liver diseases. Founded in 2015 based on research from Dr. Victor Ling's laboratory at the University of British Columbia and the BC Cancer Agency, the company leverages a proprietary tetrahydroxylated bile acid (THBA) platform. THBAs are naturally occurring, highly hydrophilic, and less cytotoxic bile acids that can stimulate bile flow and protect the liver from cholestatic injury. The company's pipeline includes QBT-006, which is in Phase 1 development for Alagille syndrome and progressive familial intrahepatic cholestasis (PFIC), and QBT-002, which is in discovery/pre-clinical development for PFIC and primary sclerosing cholangitis (PSC).